Preliminary results show that a reduced GC dose can be effective for reinducing remission in AAV, and RTX was superior to AZA at maintaining remission^4,5

• Remission induction with a reduced GC dose should be considered clinically, as it was as effective as a typical GC dose regimen
• Initial findings show RTX to be superior to AZA in reducing relapses
• Relapses still occurred in both treatment groups. By 24 months, 13% of the RTX patients and 38% of the AZA patients experienced a relapse.